Opendata, web and dolomites

ABD SIGNED

A bioengineered, naturally-derived, sustainable biocide for breaking down organic biofilms formed by drug-resistant bacteria.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ABD project word cloud

Explore the words cloud of the ABD project. It provides you a very rough idea of what is the project "ABD" about.

resistant    away    antibiotic    biofilm    biofilms    bacterial    abd    99    drug    aequor    microorganisms   

Project "ABD" data sheet

The following table provides information about the project.

Coordinator
AEQUOR LTD 

Organization address
address: 72 GREAT SUFFOLK STREET
city: LONDON
postcode: SE1 0BL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme /SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AEQUOR LTD UK (LONDON) coordinator 50˙000.00

Mappa

 Project objective

Aequor's ABD (Aequor Biofilm Dispersant) represents a significant leap forward in the arms race between modern medicine and drug-resistant bacteria. The biofilm is the first line of defence for these drug-resistant microorganisms, a polymer-like structure of proteins and secretions that protects the colony from virtually everything but burning or scraping it away.

ABD does away with this problem in dramatic fashion. A natural biocidal agent derived from marine microorganisms, ABD is devastating for bacterial contamination, but gentle enough to be used as a supplement for antibiotic treatments. It is 99.99% effective at removing existing biofilms, prevents 99.99% of new biofilms from forming, and inhibits the growth of new bacterial colonies by over 92%. Lonza Group AG has verified this stellar performance in-vitro.

Aequor intends to use the funds from the SME instrument to study the EU and global market for biocides further, and to dig deeper into markets for antibiotic supplements. Further it will carry out growth projections and examine the process for clinical trials in-depth.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

EuroXpand (2018)

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Read More  

NORMOPERF (2018)

Normothermic Perfusion Device for Renal and Hepatic Preservation and Viability Assessment

Read More  

DualDur (2018)

DualDur: A Disruptive Diagnostic Technology that Enables for the First Time an Early and Accurate Diagnosis of the tick-borne Lyme Disease.

Read More